LBA35 Primary results from TACTI-003: A randomized phase IIb trial comparing eftilagimod alpha (soluble LAG-3) plus pembrolizumab versus pembrolizumab alone in first-line recurrent or metastatic head and neck squamous cell carcinoma with CPS ≥1.
Saved in:
| Title: | LBA35 Primary results from TACTI-003: A randomized phase IIb trial comparing eftilagimod alpha (soluble LAG-3) plus pembrolizumab versus pembrolizumab alone in first-line recurrent or metastatic head and neck squamous cell carcinoma with CPS ≥1. |
|---|---|
| Authors: | Kristensen, C.A.1 (AUTHOR), Metcalf, R.2 (AUTHOR), Braña, I.3 (AUTHOR), Laban, S.4 (AUTHOR), Soria Rivas, A.5 (AUTHOR), Grose, D.6 (AUTHOR), Rubio Casadevall, J.7 (AUTHOR), Cheshuk, V.8 (AUTHOR), Dieter, S.M.9 (AUTHOR), Lopez Pousa, A.10 (AUTHOR), Kasper-Virchow, S.11 (AUTHOR), Doger de Spéville, B.12 (AUTHOR), Covela, M.13 (AUTHOR), Vogl, F.D.14 (AUTHOR), Mueller, C.15 (AUTHOR), Triebel, F.16 (AUTHOR) |
| Source: | Annals of Oncology. 2024 Supplement 2, Vol. 35, pS1227-S1227. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2024.08.2274 |
